Alex Ferenczy

TL;DR: In this paper, a double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11).

TL;DR: A strong relationship exists between persistent HPV infections and SIL incidence, particularly for HPV types 16 and 18, which is believed to be the central cause of cervical cancer.

TL;DR: Current research has focused on the determinants of infection with oncogenic HPV types, the assessment of prophylactic and therapeutic vaccines and the development of screening strategies incorporating HPV testing and other methods as adjunct to cytology, fundamental stepping stones for the implementation of effective public health programs aimed at the control of cervical cancer.

TL;DR: Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years), suggesting an anamnestic response.

TL;DR: Preursor lesions of the cervix persist longer and progress more quickly in women with oncogenic HPV infections than in womenwith non-oncogenic infections or without HPV, which may help identify those that are likely to progress rapidly.